Hans Hammers, MD

Articles by Hans Hammers, MD

Impact of the CLEAR Trial Data Updates in Clinical Practice

ByBrian I. Rini, MD,Hans Hammers, MD,Tian Zhang, MD,Moshe Ornstein, MD, MA

February 23rd 2023

The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

ByBrian I. Rini, MD,Hans Hammers, MD,Tian Zhang, MD,Moshe Ornstein, MD, MA

February 13th 2023

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

ByBrian I. Rini, MD,Hans Hammers, MD,Tian Zhang, MD,Moshe Ornstein, MD, MA

February 13th 2023

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

Hans Hammers, MD

Articles by Hans Hammers, MD

Impact of the CLEAR Trial Data Updates in Clinical Practice

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

Trending on CancerNetwork

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC